JPH0725752A - Supporting material for plaster - Google Patents
Supporting material for plasterInfo
- Publication number
- JPH0725752A JPH0725752A JP17408493A JP17408493A JPH0725752A JP H0725752 A JPH0725752 A JP H0725752A JP 17408493 A JP17408493 A JP 17408493A JP 17408493 A JP17408493 A JP 17408493A JP H0725752 A JPH0725752 A JP H0725752A
- Authority
- JP
- Japan
- Prior art keywords
- drug
- weight
- pressure
- parts
- sensitive adhesive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、貼付剤用支持体に関す
るものである。FIELD OF THE INVENTION The present invention relates to a support for patches.
【０００２】[0002]
【従来の技術】従来より、プラスター、テープ剤、パッ
チ、パップ剤等の貼付剤の支持体として、樹脂フィル
ム、樹脂発泡体、紙、織布、不織布等の単体、ならびに
これらの積層体が使用されてきた。2. Description of the Related Art Conventionally, resin films, resin foams, papers, woven fabrics, non-woven fabrics and the like as well as laminates thereof have been used as a support for plasters, tapes, patches, patches and other patches. It has been.
【０００３】しかしながら、上記支持体には、経皮吸収
性薬物との相互作用、例えば、薬物の支持体透過による
揮散、薬物の支持体中への浸透などによって、該薬物の
安定性を著しく低下さたり、貼付剤中に治療効果に必要
な量の薬物を保持することができないという問題点があ
り、薬物に応じて支持体の種類を選定する必要があっ
た。また、薬物の吸収性を向上させるために使用される
吸収助剤や溶解助剤等の種類によって、支持体の種類を
変えなければならないという問題点があった。However, the stability of the drug is remarkably lowered due to the interaction with the transdermal drug, such as volatilization of the drug by permeation of the drug into the support and penetration of the drug into the support. By the way, there is a problem that the amount of drug required for therapeutic effect cannot be retained in the patch, and it was necessary to select the type of the support according to the drug. Further, there is a problem in that the type of support must be changed depending on the type of absorption aid, dissolution aid, etc. used to improve the absorbability of the drug.
【０００４】これらの問題点を解決するために、支持体
として、薬物と相互作用のない樹脂フィルムを用いた
り、アルミニウム箔、該アルミニウム蒸着フィルムによ
り相互作用を抑制する方法が、特開昭６４−４０４２０
号公報に開示されている。In order to solve these problems, a method of using a resin film which does not interact with a drug as a support, or a method of suppressing interaction with an aluminum foil or the aluminum vapor-deposited film is disclosed in JP-A-64- 40420
It is disclosed in the publication.
【０００５】しかしながら、アルミによって作用を受け
る薬物があり、このような薬物には使用できないという
問題点があった。また、アルミニウム箔を用いた支持体
は、非常に硬く貼付時に違和感があったり、皮膚の動き
に追随しにくいために、剥がれ易いという問題点があっ
た。また、アルミ蒸着フィルムは、柔軟性を有するもの
の、アルミニウム箔と同様に金属光沢があり、外観が目
立ち過ぎるため、印刷を施したり、着色樹脂フィルムを
積層する等の工夫を必要とした。However, there is a problem that some drugs are affected by aluminum and cannot be used for such drugs. In addition, the support using an aluminum foil is very hard and feels uncomfortable when applied, and it is difficult to follow the movement of the skin, so that it is easily peeled off. Further, although the aluminum vapor deposition film has flexibility, it has metallic luster similarly to the aluminum foil and its appearance is too conspicuous. Therefore, it is necessary to perform printing or laminating a colored resin film.
【０００６】[0006]
【発明が解決しようとする課題】本発明は、上記欠点に
鑑みてなされたものであり、その目的は、薬物を透過せ
ず、かつ薬物を浸透、分解させることがなく、長期保存
安定性に優れると共に使用感の優れた貼付剤用支持体を
提供することにある。SUMMARY OF THE INVENTION The present invention has been made in view of the above-mentioned drawbacks, and its purpose is to prevent long-term storage stability without allowing the drug to permeate and not permeating or degrading the drug. An object is to provide a support for patches, which is excellent as well as excellent in usability.
【０００７】[0007]
【課題を解決するための手段】本発明の貼付剤用支持体
は、樹脂フィルムの少なくとも片面に、ケイ素酸化物の
被膜を形成したものである。The patch support of the present invention comprises a resin film having a silicon oxide coating film formed on at least one surface thereof.
【０００８】上記樹脂フィルムに使用される樹脂として
は、例えば、ポリエチレン、ポリプロピレン、ポリイソ
プレン、ポリブテン、ポリブチレン、ポリブタジエン等
のポリオレフィン；ポリオレフィンと、エチレン−酢酸
ビニル共重合体、塩化ビニル、ビニルアルコール、（メ
タ）アクリル酸、（メタ）アクリル酸エステル等との共
重合体；ポリエチレンテレフタテート、ポリブチレンテ
レフタテート、ポリエチレンアジペート等のポリエステ
ル；ポリ塩化ビニル、ポリ塩化ビニリデン、ポリフッ化
ビニリデン、ポリテトラフルオロエチレン等のポリエチ
レンハロゲン置換体；スチレン−イソプレン−スチレン
ブロック共重合体、スチレン−ブタジエン−スチレンブ
ロック共重合体、スチレン−エチレン−ブタジエン−ス
チレンブロック共重合体等の合成ゴム；可塑化ポリ塩化
ビニル；可塑化酢酸ビニル−塩化ビニル共重合体；ポリ
ビニルアルコール；ポリウレタン；ポリアミド；ポリア
クリル；酢酸セルロース、メチルセルロース、エチルセ
ルロース等のセルロース誘導体；天然ゴム等が挙げられ
る。Examples of the resin used for the resin film include polyolefins such as polyethylene, polypropylene, polyisoprene, polybutene, polybutylene and polybutadiene; polyolefins, ethylene-vinyl acetate copolymers, vinyl chloride, vinyl alcohol, ( Copolymers with (meth) acrylic acid, (meth) acrylic acid ester, etc .; polyesters such as polyethylene terephthalate, polybutylene terephthalate, polyethylene adipate; polyvinyl chloride, polyvinylidene chloride, polyvinylidene fluoride, polytetrafluoro Polyethylene halogen substitution products such as ethylene; styrene-isoprene-styrene block copolymer, styrene-butadiene-styrene block copolymer, styrene-ethylene-butadiene-styrene block copolymer Synthetic rubber such as coalesce; plasticized polyvinyl chloride; plasticized vinyl acetate-vinyl chloride copolymer; polyvinyl alcohol; polyurethane; polyamide; polyacryl; cellulose derivatives such as cellulose acetate, methyl cellulose, ethyl cellulose; natural rubber and the like. .
【０００９】上記樹脂フィルムの厚さは、樹脂フィルム
の硬さや強度によって異なるが、薄くなると使用上又は
製造上必要な強度が得られず、厚くなると硬くなって柔
軟性が失われ、使用感が悪くなるので、１〜１，０００
μｍが好ましく、より好ましくは５〜３００μｍであ
る。The thickness of the resin film varies depending on the hardness and strength of the resin film. When the resin film becomes thin, the strength required for use or manufacturing cannot be obtained. When the resin film becomes thick, the resin film becomes hard and loses flexibility, resulting in a feeling of use. 1 to 1,000 because it gets worse
μm is preferable, and more preferably 5 to 300 μm.
【００１０】上記ケイ素酸化物被膜の厚さは、薄くなる
と薬物の透過を抑制する効果が小さく、一定以上に厚く
なっても薬物の透過を抑制する効果は向上せず、被膜に
亀裂が生じ易くなるので、１００〜１０，０００Åに限
定され、好ましくは２００〜３，０００Åである。When the thickness of the above-mentioned silicon oxide coating is small, the effect of suppressing the permeation of the drug is small, and even when it is thicker than a certain value, the effect of suppressing the permeation of the drug is not improved, and the film is easily cracked. Therefore, it is limited to 100 to 10,000 Å, preferably 200 to 3,000 Å.
【００１１】上記樹脂フィルム上にケイ素酸化物被膜を
形成する方法としては、例えば、真空蒸着法が挙げられ
る。As a method for forming a silicon oxide film on the resin film, there is, for example, a vacuum vapor deposition method.
【００１２】本発明の貼付剤用支持体の構成は上述した
通りであるが、必要に応じて、上記貼付剤用支持体の少
なくとも片面に、紙、織布、不織布及び樹脂フィルムか
らなる群より選ばれる少なくとも１種以上の材料が積層
されてもよい。The constitution of the patch support of the present invention is as described above. If necessary, at least one surface of the patch support may be composed of a group consisting of paper, woven cloth, non-woven fabric and resin film. At least one selected material may be laminated.
【００１３】上記織布及び不織布としては、例えば、
綿、絹、麻などの天然繊維；上記樹脂フィルムに用いら
れる樹脂の繊維を素材とするものが挙げられる。Examples of the woven and non-woven fabrics include
Natural fibers such as cotton, silk, and hemp; those made from the fibers of the resin used for the resin film can be mentioned.
【００１４】上記樹脂フィルムとしては、上記支持体に
用いられる樹脂フィルムが好適に使用される。As the resin film, the resin film used for the support is preferably used.
【００１５】上記貼付剤用支持体と、紙、織布、不織布
及び樹脂フィルムを積層する方法としては、接着剤によ
る接着法、熱融着法等が挙げられる。Examples of the method for laminating the above-mentioned patch support, paper, woven cloth, non-woven cloth and resin film include an adhesive bonding method and a heat fusion method.
【００１６】上記貼付剤用支持体において、紙、織布、
不織布及び樹脂フィルム等が積層された側に粘着剤層が
設けられる場合は、薬物を透過、分解させないものを使
用するのが好ましい。In the above-mentioned patch support, paper, woven fabric,
When the pressure-sensitive adhesive layer is provided on the side where the non-woven fabric, the resin film and the like are laminated, it is preferable to use one that does not allow the drug to permeate or decompose.
【００１７】本発明の貼付剤用支持体を用いて貼付剤を
製造する場合は、通常、その片面に薬物を含有する粘着
剤層が形成される。この粘着剤層は、ケイ素酸化物被膜
側に形成されるのが好ましい。When a patch is produced using the patch support of the present invention, a pressure-sensitive adhesive layer containing a drug is usually formed on one side thereof. This pressure-sensitive adhesive layer is preferably formed on the silicon oxide coating side.
【００１８】上記粘着剤層に使用される粘着剤組成物と
しては、薬物を貯蔵保持し、皮膚に対して感圧接着性を
有するものであれば特に制限されず、例えば、アクリル
系粘着剤、ビニルエーテル系粘着剤、シリコーン系粘着
剤、天然ゴムや合成ゴムを用いたゴム系粘着剤等を主成
分とするものが挙げられる。また、上記粘着剤組成物に
は、凝集力や粘着力を調節するために架橋処理が施され
たり、酸化防止剤、充填剤、安定剤、薬物の経皮吸収性
を向上させる助剤等が添加されてもよい。The pressure-sensitive adhesive composition used in the pressure-sensitive adhesive layer is not particularly limited as long as it stores and retains a drug and has pressure-sensitive adhesiveness to the skin. For example, an acrylic pressure-sensitive adhesive, Examples thereof include those containing vinyl ether-based adhesives, silicone-based adhesives, rubber-based adhesives using natural rubber or synthetic rubber as a main component. Further, the above-mentioned pressure-sensitive adhesive composition is subjected to a crosslinking treatment in order to adjust cohesive force or pressure-sensitive adhesive force, an antioxidant, a filler, a stabilizer, an auxiliary agent for improving the transdermal absorbability of a drug, and the like. It may be added.
【００１９】上記薬物は、経皮又は経粘膜により体内に
吸収されるものであれば特に限定されないが、ケイ素酸
化物被膜の形成された支持体に効果的な薬物としては、
例えば、融点の低い揮発性の薬物、合成樹脂に対する透
過性の高い薬物、安定性の悪い薬物等が挙げられ、具体
的には、ｌ−メントール、カンフル、はっか油等の精
油；サリチル酸グリコール、硝酸イソソルビド、ニトロ
グリセリン等が例示される。The above-mentioned drug is not particularly limited as long as it is absorbed into the body by transdermal or transmucosal, but as a drug effective for a support having a silicon oxide film formed thereon,
Examples thereof include volatile drugs having a low melting point, drugs having high permeability to synthetic resins, drugs having poor stability, and the like. Specifically, essential oils such as l-menthol, camphor, and mackerel oil; glycol salicylate, nitric acid. Examples thereof include isosorbide and nitroglycerin.
【００２０】上記薬物の使用量は、少なくなると十分な
薬効が得られず、一定量以上多くなってもそれ以上の薬
効が得られず、逆に粘着剤層に悪影響を与えるので、粘
着剤組成物１００重量部に対して、０．１〜３０重量部
が好ましく、より好ましくは０．５〜２５重量部であ
る。If the amount of the above-mentioned drug used is too small, sufficient drug effect cannot be obtained, and if it exceeds a certain amount, further drug effect cannot be obtained, and adversely affects the pressure-sensitive adhesive layer. The amount is preferably 0.1 to 30 parts by weight, more preferably 0.5 to 25 parts by weight, based on 100 parts by weight of the product.
【００２１】上記樹脂フィルムに粘着剤層を形成する方
法としては、通常の粘着テープの製造に用いられている
方法が採用され、例えば、薬物を含有する粘着剤組成物
を、ロールコーター等により直接樹脂フィルムに塗工す
る方法や、薬物を含有する粘着剤組成物を剥離性フィル
ム上に塗工乾燥して一旦粘着剤層を形成し、該粘着剤層
を樹脂フィルムに転写する方法等が挙げられる。As a method for forming the pressure-sensitive adhesive layer on the resin film, a method used in the production of ordinary pressure-sensitive adhesive tapes is adopted. For example, a pressure-sensitive adhesive composition containing a drug is directly applied by a roll coater or the like. Examples include a method of coating on a resin film, a method of coating a pressure-sensitive adhesive composition containing a drug on a peelable film and drying it to once form a pressure-sensitive adhesive layer, and transferring the pressure-sensitive adhesive layer to a resin film. To be
【００２２】[0022]
【実施例】以下、本発明の実施例を説明する。アクリル系粘着剤の調製 温度計、攪拌機、還流冷却管、窒素ガス導入管を備えた
反応器内に、メタクリル酸−２−エチルヘキシル１８０
重量部、アクリル酸−２−エチルヘキシル６０重量部及
び酢酸エチル１００重量部を仕込み、この混合物を窒素
気流下にて攪拌しながら８０℃に加熱し、反応系が７０
℃に達した時点から、シクロヘキサン１００重量部に過
酸化ラウロイル０．２重量部を溶解した重合開始剤を６
時間かけて滴下し重合反応を行い、重量平均分子量１０
５万、固形分５８重量％のアクリル系粘着剤を得た。EXAMPLES Examples of the present invention will be described below. Preparation of acrylic pressure-sensitive adhesive In a reactor equipped with a thermometer, a stirrer, a reflux condenser and a nitrogen gas inlet tube, 2-ethylhexyl methacrylate 180 was added.
Parts by weight, 60 parts by weight of 2-ethylhexyl acrylate and 100 parts by weight of ethyl acetate were charged, and the mixture was heated to 80 ° C. with stirring under a nitrogen stream, and the reaction system was adjusted to 70%.
From the time when the temperature reached ℃, 6 parts of a polymerization initiator prepared by dissolving 0.2 parts by weight of lauroyl peroxide in 100 parts by weight of cyclohexane was added.
Polymerization reaction is carried out by dropping over a period of time to obtain a weight average molecular weight of 10
An acrylic pressure-sensitive adhesive having 50,000 and a solid content of 58% by weight was obtained.
【００２３】ゴム系粘着剤の調製 スチレン−イソプレン−スチレンブロック共重合体（シ
ェル化学社製「カリフレックスＴＲ１１０７」）１５０
重量部、脂環族飽和炭化水素樹脂（荒川化学社製「アル
コンＰ−９０」）３００重量部、ポリブテン（日本石油
化学社製「ＨＶ−３００Ｆ」）１００重量部及び流動パ
ラフィン（日興製薬社製、日本薬局方）４５０重量部を
セパラブルフラスコ中に入れ、窒素気流下にて１５０℃
で６時間攪拌し溶解均一化しゴム系粘着剤を得た。Preparation of Rubber Adhesive Styrene-isoprene-styrene block copolymer ("Califlex TR1107" manufactured by Shell Chemical Co.) 150
Parts by weight, 300 parts by weight of alicyclic saturated hydrocarbon resin ("Arcon P-90" manufactured by Arakawa Chemical Co., Ltd.), 100 parts by weight of polybutene ("HV-300F" manufactured by Nippon Petrochemical Co., Ltd.) and liquid paraffin (manufactured by Nikko Pharmaceutical Co., Ltd.). , Japanese Pharmacopoeia) 450 parts by weight in a separable flask and 150 ° C. under a nitrogen stream.
The mixture was stirred for 6 hours and dissolved and homogenized to obtain a rubber-based pressure-sensitive adhesive.
【００２４】ケイ素酸化物被膜の形成方法 電子ビーム加熱式真空蒸着装置の真空槽内上部の基材取
付治具に３０×３０ｃｍの樹脂フィルムを取り付け、真
空槽内下部の坩堝にＳｉＯ2 を充填し槽内の圧力を１×
１０-5Ｔｏｒｒに減圧した。次いで、電子銃から電子ビ
ームを坩堝に照射しＳｉＯ2 を蒸発させ、樹脂フィルム
上にケイ素酸化物被膜を形成した。上記被膜の厚さは、
樹脂フィルムの一部をあらかじめマスキングしておき、
触針粗さ測定装置（スローン社製「Ｄｅｋｆａｋ３０３
０」）により測定した。 Method for forming silicon oxide coating A 30 × 30 cm resin film is attached to a base material mounting jig in the upper part of the vacuum chamber of an electron beam heating type vacuum deposition apparatus, and SiO 2 is filled in a crucible in the lower part of the vacuum chamber. 1 × the pressure in the tank
The pressure was reduced to 10 −5 Torr. Next, the crucible was irradiated with an electron beam from an electron gun to evaporate SiO 2 and form a silicon oxide film on the resin film. The thickness of the film is
Mask a part of the resin film in advance,
Stylus roughness measuring device ("Dekfak303" manufactured by Sloan)
0 ").
【００２５】（実施例１）上記アクリル系粘着剤９５重
量部及び硝酸イソソルビド５重量部を酢酸エチル３００
重量部に均一に溶解し、この溶液をポリエチレンコート
グラシン紙上に、乾燥後の厚さが１００μｍとなるよう
にナイフコーターを用いて展延し、６０℃で乾燥させ粘
着剤層を形成した。次いで、真空蒸着により、厚さ３０
０Åのケイ素酸化物の被膜を形成した厚さ２５μｍの二
軸延伸ポリプロピレンフィルム（以下「ＯＰＰ」とい
う）支持体のケイ素酸化物被膜側に、上記粘着剤層を転
写し貼付剤を得た。Example 1 95 parts by weight of the acrylic adhesive and 5 parts by weight of isosorbide dinitrate were mixed with 300 parts of ethyl acetate.
The solution was uniformly dissolved in parts by weight, and the solution was spread on polyethylene-coated glassine paper using a knife coater so that the thickness after drying was 100 μm, and dried at 60 ° C. to form an adhesive layer. Then, by vacuum evaporation, the thickness 30
The pressure-sensitive adhesive layer was transferred to the silicon oxide film side of a 25 μm thick biaxially oriented polypropylene film (hereinafter referred to as “OPP”) support on which a 0Å silicon oxide film was formed to obtain a patch.
【００２６】（実施例２）上記アクリル系粘着剤８５重
量部、硝酸イソソルビド５重量部及びミリスチン酸イソ
プロピル１０重量部を酢酸エチル３００重量部に均一に
溶解し、この溶液から、実施例１と同様にして乾燥後の
厚さが１００μｍの粘着剤層を形成した。次いで、真空
蒸着により、厚さ２，５００Åのケイ素酸化物の被膜を
形成した厚さ２５μｍのＯＰＰ支持体に、実施例１と同
様にして、上記粘着剤層を転写し貼付剤を得た。Example 2 85 parts by weight of the acrylic adhesive, 5 parts by weight of isosorbide dinitrate and 10 parts by weight of isopropyl myristate were uniformly dissolved in 300 parts by weight of ethyl acetate. From this solution, the same procedure as in Example 1 was carried out. Then, a pressure-sensitive adhesive layer having a thickness after drying of 100 μm was formed. Then, the pressure-sensitive adhesive layer was transferred to a 25 μm-thick OPP support on which a 2,500 Å-thick silicon oxide film was formed by vacuum vapor deposition in the same manner as in Example 1 to obtain a patch.
【００２７】（実施例３）上記アクリル系粘着剤９２重
量部、ｌ−メントール３重量部及びミリスチン酸イソプ
ロピル５重量部を酢酸エチル３００重量部に均一に溶解
し、この溶液から、実施例１と同様にして乾燥後の厚さ
が１００μｍの粘着剤層を形成した。次いで、真空蒸着
により、厚さ１，０００Åのケイ素酸化物の被膜を形成
した厚さ４０μｍのＯＰＰ支持体に、実施例１と同様に
して、上記粘着剤層を転写し貼付剤を得た。(Example 3) 92 parts by weight of the acrylic adhesive, 3 parts by weight of 1-menthol and 5 parts by weight of isopropyl myristate were uniformly dissolved in 300 parts by weight of ethyl acetate, and from this solution, the solution of Example 1 was obtained. Similarly, a pressure-sensitive adhesive layer having a thickness after drying of 100 μm was formed. Then, the pressure-sensitive adhesive layer was transferred to a 40 μm-thick OPP support on which a 1,000-Å-thick silicon oxide film was formed by vacuum vapor deposition in the same manner as in Example 1 to obtain a patch.
【００２８】（実施例４）上記ゴム系粘着剤１００重量
部を配合瓶に秤取し、１５０℃に加熱し溶融した後、サ
リチル酸グリコール６重量部及びｌ−メントール０．５
重量部の混合物を溶融したゴム系粘着剤に加え均一に溶
解した。この溶液を離型処理したポリエチレンテレフタ
レート（以下「ＰＥＴ」という）フィルム上に、乾燥後
の厚さが１００μｍとなるようにナイフコーターを用い
て展延した後、室温まで放冷し粘着剤層を形成した。次
いで、真空蒸着により、厚さ１，０００Åのケイ素酸化
物の被膜を形成した厚さ５０μｍのポリ塩化ビニルフィ
ルム支持体に、実施例１と同様にして、上記粘着剤層を
転写し貼付剤を得た。Example 4 100 parts by weight of the above rubber-based adhesive was weighed into a compounding bottle, heated to 150 ° C. and melted, and then 6 parts by weight of glycol salicylate and 0.5 parts of 1-menthol.
Part by weight of the mixture was added to the molten rubber-based pressure-sensitive adhesive and uniformly dissolved. This solution was spread on a polyethylene terephthalate (hereinafter referred to as “PET”) film subjected to release treatment using a knife coater so that the thickness after drying was 100 μm, and then allowed to cool to room temperature to form an adhesive layer. Formed. Then, the above-mentioned pressure-sensitive adhesive layer was transferred to a polyvinyl chloride film support having a thickness of 50 μm and formed with a 1,000 Å-thick silicon oxide film by vacuum deposition in the same manner as in Example 1 to give a patch. Obtained.
【００２９】（実施例５）上記ゴム系粘着剤３９重量部
を配合瓶に秤取し、１５０℃に加熱し溶融した後、イン
ドメタシン２重量部及びクロタミトン５重量部の混合物
を溶融したゴム系粘着剤に加え均一に溶解した。この溶
液を離型処理したＰＥＴフィルム上に、乾燥後の厚さが
１００μｍとなるようにナイフコーターを用いて展延し
た後、室温まで放冷し粘着剤層を形成した。次いで、真
空蒸着により、厚さ１，０００Åのケイ素酸化物の被膜
を形成したポリエチレンフィルム（２０μｍ厚）のケイ
素酸化物被膜側に、ＰＥＴフィルム（１２μｍ厚）を積
層した積層支持体のＰＥＴ側に、上記粘着剤層を転写し
貼付剤を得た。Example 5 39 parts by weight of the above-mentioned rubber-based adhesive was weighed into a compounding bottle, heated to 150 ° C. and melted, and then a mixture of 2 parts by weight of indomethacin and 5 parts by weight of crotamiton was melted to obtain a rubber-based adhesive. It was added to the agent and dissolved uniformly. This solution was spread on a PET film subjected to release treatment using a knife coater so that the thickness after drying was 100 μm, and then allowed to cool to room temperature to form an adhesive layer. Then, on the PET side of the laminated support in which the PET film (12 μm thick) was laminated on the silicon oxide film side of the polyethylene film (20 μm thick) on which a 1,000 Å-thick silicon oxide film was formed by vacuum deposition. Then, the adhesive layer was transferred to obtain a patch.
【００３０】（実施例６）上記アクリル系粘着剤８０重
量部、ニトログリセリン１５重量部及びミリスチン酸イ
ソプロピル５重量部を酢酸エチル３００重量部に均一に
溶解し、この溶液から、実施例１と同様にして乾燥後の
厚さが１００μｍの粘着剤層を形成した。次いで、真空
蒸着により、厚さ１，０００Åのケイ素酸化物の被膜を
形成した厚さ１２μｍのＰＥＴフィルム支持体に、実施
例１と同様にして、上記粘着剤層を転写し貼付剤を得
た。Example 6 80 parts by weight of the above acrylic adhesive, 15 parts by weight of nitroglycerin and 5 parts by weight of isopropyl myristate were uniformly dissolved in 300 parts by weight of ethyl acetate, and from this solution, the same as in Example 1 was performed. Then, a pressure-sensitive adhesive layer having a thickness after drying of 100 μm was formed. Then, the pressure-sensitive adhesive layer was transferred to a 12 μm-thick PET film support having a 1,000 Å-thick silicon oxide film formed thereon by vacuum vapor deposition in the same manner as in Example 1 to obtain a patch. .
【００３１】（比較例１）ケイ素酸化物の被膜を形成し
ていない２５μｍ厚のＯＰＰフィルムを使用したこと以
外は、実施例１と同様にして貼付剤を得た。(Comparative Example 1) A patch was obtained in the same manner as in Example 1 except that an OPP film having a thickness of 25 µm on which a silicon oxide film was not formed was used.
【００３２】（比較例２）ケイ素酸化物の被膜を形成し
ていない２５μｍ厚のＯＰＰフィルムを使用したこと以
外は、実施例２と同様にして貼付剤を得た。(Comparative Example 2) A patch was obtained in the same manner as in Example 2 except that an OPP film having a thickness of 25 µm on which a silicon oxide film was not formed was used.
【００３３】（比較例３）実施例５で得られた粘着剤層
を、アルミ箔（９μｍ厚）／ポリエチレンフィルム（２
０μｍ厚）／ＰＥＴフィルム（１２μｍ厚）の積層支持
体のＰＥＴ側に転写し、貼付剤を得た。Comparative Example 3 The pressure-sensitive adhesive layer obtained in Example 5 was replaced with aluminum foil (9 μm thick) / polyethylene film (2
(0 μm thickness) / PET film (12 μm thickness) was transferred to the PET side of the laminated support to obtain a patch.
【００３４】上記実施例及び比較例で得られた貼付剤用
支持体及び貼付剤につき、下記の評価を行った。 （１）貼付剤用支持体の薬物透過性及び薬物浸透性 粘着剤組成物を４０μｍ厚のポリエチレンフィルムに積
層して粘着剤層を形成した後、直径２ｃｍの円形に打ち
抜き、上記実施例及び比較例で用いられた各支持体（直
径４ｃｍの円形）の一方に貼付し、さらに、この支持体
の他方に、上記実施例及び比較例に対応して、それぞれ
薬物を含まない粘着剤組成物を各支持体に塗工乾燥して
得られた粘着テープを貼付して試料を得た。次いで、こ
の試料のポリエチレンフィルムを剥離した後、試料全体
をアルミホイールで密封し、６０℃で１０日間保存し
た。保存後の試料から、粘着剤層、支持体及び粘着テー
プを別々に剥離して、各々の薬物をメタノールで抽出
し、高速液体クロマトグラフを用いて薬物の定量を行っ
た。粘着剤層中の薬物量の初期値を１００とし、粘着剤
層、支持体及び粘着テープにおける薬物量をそれぞれ比
率で表した結果を表１に示した。The following evaluations were carried out on the patch support and patch obtained in the above Examples and Comparative Examples. (1) Drug permeability and drug permeability of patch support A pressure-sensitive adhesive composition was laminated on a polyethylene film having a thickness of 40 μm to form a pressure-sensitive adhesive layer, which was then punched into a circle having a diameter of 2 cm. It was attached to one of the respective supports (circles having a diameter of 4 cm) used in the examples, and further, on the other side of the supports, corresponding to the above-mentioned Examples and Comparative Examples, an adhesive composition containing no drug was prepared. The adhesive tape obtained by coating and drying was applied to each support to obtain a sample. Then, after peeling off the polyethylene film of this sample, the whole sample was sealed with an aluminum wheel and stored at 60 ° C. for 10 days. The adhesive layer, the support and the adhesive tape were separately peeled from the sample after storage, each drug was extracted with methanol, and the drug was quantified using a high performance liquid chromatograph. The initial value of the amount of drug in the pressure-sensitive adhesive layer was set to 100, and the amount of drug in the pressure-sensitive adhesive layer, the support and the pressure-sensitive adhesive tape was expressed as a ratio, and the results are shown in Table 1.
【００３５】（２）薬物保存安定性 上記実施例及び比較例で得られた貼付剤を直径２ｃｍの
円形に打ち抜いたものを試料とし、この試料をアルミホ
イルで密封し６０℃で１０日間保存した。保存後の試料
中の薬物をメタノールで抽出し、高速液体クロマトグラ
フを用いて薬物の定量を行った。粘着剤層中の薬物量の
初期値を１００とし、その残量を比率で表した結果を表
２に示した。(2) Storage stability of drug The patch obtained in each of the above Examples and Comparative Examples was punched out into a circle having a diameter of 2 cm and used as a sample. The sample was sealed with aluminum foil and stored at 60 ° C. for 10 days. . The drug in the sample after storage was extracted with methanol, and the drug was quantified using a high performance liquid chromatograph. The initial value of the amount of drug in the pressure-sensitive adhesive layer was set to 100, and the remaining amount was expressed as a ratio, and the results are shown in Table 2.
【００３６】[0036]
【表１】 [Table 1]
【００３７】[0037]
【表２】 [Table 2]
【００３８】[0038]
【発明の効果】本発明の貼付剤用支持体は、上述した構
成であり、薬物を透過せず、かつ薬物を透過、分解させ
ることがないので、長期保存安定性に優れる共に使用感
の優れた貼付剤を提供する。EFFECTS OF THE INVENTION The support for patches of the present invention has the above-mentioned constitution and does not permeate a drug, and does not permeate or decompose a drug, so that it is excellent in long-term storage stability and is excellent in usability. To provide a patch.
Claims (1)
００〜１０，０００Åのケイ素酸化物被膜が積層されて
いることを特徴とする貼付剤用支持体。1. A resin film having a thickness of 1 on at least one side.
A support for an adhesive patch, which comprises a silicon oxide coating of 0.001 to 10,000 Å laminated.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP17408493A JP3192829B2 (en) | 1993-07-14 | 1993-07-14 | Patch support |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP17408493A JP3192829B2 (en) | 1993-07-14 | 1993-07-14 | Patch support |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0725752A true JPH0725752A (en) | 1995-01-27 |
| JP3192829B2 JP3192829B2 (en) | 2001-07-30 |
Family
ID=15972376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP17408493A Expired - Fee Related JP3192829B2 (en) | 1993-07-14 | 1993-07-14 | Patch support |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3192829B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009249298A (en) * | 2008-04-02 | 2009-10-29 | Toppan Printing Co Ltd | Support for plaster and plaster using the same and method for producing support for plaster |
-
1993
- 1993-07-14 JP JP17408493A patent/JP3192829B2/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009249298A (en) * | 2008-04-02 | 2009-10-29 | Toppan Printing Co Ltd | Support for plaster and plaster using the same and method for producing support for plaster |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3192829B2 (en) | 2001-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR950015057B1 (en) | Transdermal therapeutic system with physostigmine as active component | |
| JP5308149B2 (en) | Non-fiber transdermal therapeutic system and manufacturing method thereof | |
| JP5171703B2 (en) | Medical adhesive emulsion made of ethylene-vinylacetic acid copolymer and adhesive resin | |
| JPH07138153A (en) | Percutaneous supply of effective medicine | |
| IE64200B1 (en) | Transdermal therapeutical system comprising physostigmine as active component and process for the production thereof | |
| JP3523259B2 (en) | Plasters containing volatile active substances that can be produced without solvents | |
| CA2550704C (en) | Nicotine transdermal delivery system | |
| NO301049B1 (en) | Process for preparing a plastics formulation with high content of plasticizers | |
| CA2264524A1 (en) | Patch | |
| JP2004507489A (en) | Transdermal therapeutic system for releasing venlafaxine | |
| WO1998030210A1 (en) | Patch containing isosorbide dinitrate | |
| CA2642338A1 (en) | Adhesive preparation comprising sufentanil and methods of using the same | |
| WO1998051288A1 (en) | Patch preparations for percutaneous absorption | |
| EP0968713B1 (en) | Plasters containing isosorbide nitrate | |
| JP3575616B2 (en) | Patch structure | |
| JP3192829B2 (en) | Patch support | |
| JPH07116023B2 (en) | Patch using polyurethane film as support | |
| JP2003104875A (en) | Device for slow release medicine | |
| JP2006169160A (en) | Plaster for external use and method for producing the same | |
| JP2007022939A (en) | Plaster for external use | |
| US6623763B2 (en) | Pharmaceutical preparation adhering to the skin, in particular a transdermal therapeutic system for the release of 17-β-estradiol to the human organism | |
| JPH0495023A (en) | Sustained release plaster | |
| JPH10504313A (en) | Estradiol transdermal formulation with water-binding additive | |
| JP3098095B2 (en) | Patch using a moisture-permeable support | |
| JP4344175B2 (en) | Method for producing matrix-type transdermal preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |